# Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

> **NCT01177813** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 986 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Placebo identical to BI10773 high dose
- **DRUG:** BI 10773
- **DRUG:** BI 10773 open label
- **DRUG:** Placebo identical to BI10773 low dose
- **DRUG:** Placebo identical to BI10773 low dose
- **DRUG:** Placebo identical to BI10773 high dose
- **DRUG:** Placebo identical to Sitagliptin 100mg
- **DRUG:** Placebo identical to Sitagliptin 100mg
- **DRUG:** BI10773
- **DRUG:** Sitagliptin
- **DRUG:** Placebo identical to Sitagliptin 100mg
- **DRUG:** Placebo identical to BI10773 low dose
- **DRUG:** Placebo identical to BI10773 high dose

## Key facts

- **NCT ID:** NCT01177813
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2012-03
- **Final completion:** —
- **Target enrollment:** 986 (ACTUAL)
- **Last updated:** 2014-06-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01177813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01177813, "Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01177813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*